A detailed history of Raymond James Financial Inc transactions in Editas Medicine, Inc. stock. As of the latest transaction made, Raymond James Financial Inc holds 163,888 shares of EDIT stock, worth $426,108. This represents 0.0% of its overall portfolio holdings.

Number of Shares
163,888
Previous 182,118 10.01%
Holding current value
$426,108
Previous $400,000 42.0%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 14, 2025

SELL
$2.2 - $3.52 $40,106 - $64,169
-18,230 Reduced 10.01%
163,888 $568,000
Q2 2025

Aug 14, 2025

SELL
$0.98 - $2.35 $15,041 - $36,067
-15,348 Reduced 7.77%
182,118 $400,000
Q1 2025

May 13, 2025

SELL
$1.14 - $3.2 $47,311 - $132,803
-41,501 Reduced 17.37%
197,466 $229,000
Q4 2024

Feb 06, 2025

BUY
$1.2 - $3.76 $286,760 - $898,515
238,967 New
238,967 $303,000

Others Institutions Holding EDIT

About Editas Medicine, Inc.


  • Ticker EDIT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 68,737,200
  • Market Cap $179M
  • Description
  • Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...
More about EDIT
Track This Portfolio

Track Raymond James Financial Inc Portfolio

Follow Raymond James Financial Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James Financial Inc, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James Financial Inc with notifications on news.